The leading representative office of defined VC is situated in the London. The company was established in Europe in United Kingdom.
The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this UCL Technology Fund works on 9 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018.
Among the various public portfolio startups of the fund, we may underline Orchard Therapeutics, Hazy, MediaGamma Among the most popular fund investment industries, there are Genetics, Artificial Intelligence. The fund has exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The overall number of key employees were 1.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the UCL Technology Fund, startups are often financed by UCLB, Syncona Partners LLP, Nesta Impact Investments. The meaningful sponsors for the fund in investment in the same round are London Co-Investment Fund, AI Seed, UCLB. In the next rounds fund is usually obtained by Syncona Partners LLP, Venrock, UCLB.
|Anna Partners||Israel, Tel Aviv, Tel Aviv District|
|Buongiorno||Emilia-Romagna, Italy, Parma|
|Canson Capital Partners||England, London, United Kingdom|
|Dresdner Kleinwort||England, London, United Kingdom|
|FountainVest Partners||China, Hong Kong, Hong Kong Island|
|Goldman Sachs Asset Management||New York, New York, United States|
|Hengjian Holding||China, Guangdong Province, Huizhou|
|Hoshino Resorts||Japan, Nagano, Nagano Prefecture|
|Huashu Chuanmei||China, Hangzhou, Zhejiang|
|Ingram Content Group||La Vergne, Tennessee, United States|
|Lantern Capital||Central, Central Region, Singapore|
|Merck Capital Ventures||New Jersey, United States, Woodcliff Lake|
|Sharrp Ventures||India, Maharashtra, Mumbai|
|Shibolet Capital||Israel, Tel Aviv, Tel Aviv District|
|SRB Management||Dallas, Texas, United States|
|Technostarters Fonds Zuid-Nederland B.V.||Eindhoven, Noord-Brabant, The Netherlands|
|The Bonte Family Fund||-|
|The Hale Group||Danvers, Massachusetts, United States|
|TransLink||British Columbia, Burnaby, Canada|
|$47M||14 Feb 2022||London, England, United Kingdom|
|$1M||20 Oct 2021||London, England, United Kingdom|
|$137M||17 Jun 2021||United Kingdom, England, United Kingdom|
Intrinsic Semiconductor Technologies
|$1M||22 Mar 2021||London, England, United Kingdom|
|$40M||11 Feb 2021||United Kingdom, England|
|$2M||18 Nov 2020||London, England, United Kingdom|
|$6M||03 Aug 2020||London, England, United Kingdom|
|29 Jul 2020||London, England, United Kingdom|
|$1M||24 Mar 2020||United Kingdom, England, United Kingdom|
– Apollo Therapeutics completed a $145m financing round.
– The round was led by Patient Square Capital and included participation from Rock Springs Capital, Reimagined Ventures and UCL Technology Fund.
– Apollo is a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries.
– Apollo is set-up to bridge the gap from deep academic science to patient benefit in the most capital and time efficient way possible.
– Apollo seeks to develop therapeutics that have transformative potential above the current standard of care.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.